No correlation between PD-L1 and NIS expression in lymph node metastatic papillary thyroid carcinoma

Author:

Levay Bernadett1,Kiss Alexandra1,Fröhlich Georgina1,Tóth Erika1,Slezák András1,Peter Ilona1,Oberna Ferenc1,Dohán Orsolya1

Affiliation:

1. National Institute of Oncology

Abstract

Abstract

Background: About 90% of thyroid cancers originate from follicular epithelial cells as differentiated thyroid cancer (DTC). 90% of DTC is papillary thyroid cancer (PTC), 10% is follicular thyroid cancer (FTC). The standard of care for PTC is surgery followed by radioiodine (RAI) ablation and thyroid stimulating hormone (TSH) suppressive therapy. The treatment of radioiodine refracter DTC is challenging. While during malignant transformation thyroid epithelial cells lose their ability to accumulate radioiodine (due to impaired membrane targeting or lacking NIS expression), it has recently been reported that PD-L1 expression in thyroid cancer cells increases during dedifferentiation. Since NIS and PD-L1 expression has never been investigated together in thyroid cancer, the aim of our present study was to investigate and correlate PD-L1 and NIS expression in the same primary tumor samples of lymph node metastatic PTC. Methods: The expression of hNIS (human natrium/sodium iodide symporter) and PD-L1 was studied by immunohistochemistry analyses in primary tumor samples of metastatic PTC patients. Results: PD-L1 and NIS immunohistochemistry analysis was performed in 89 and 86 PTC cases, respectively. 25 tumors did not show PDL1 expression, while in 58 tumors, 1-50% of the tumor cells showed PD-L1 expression, and in 6 tumors more than 50% of the cells were positive for PD-L1. NIS immunohistochemistry was performed on 86 primary papillary carcinomas. 51 out of 86 tumors showed NIS expression, only in 7 cases NIS was localized in the plasma membrane, while in most tumors NIS was retained in the intracytoplasmic membrane compartments. Conclusion: No correlation was found between PD-L1 and NIS expression. It is tempting to speculate whether manipulation of the PD1/PDL1 axis by anti-PDL1 or anti-PD1 antibodies, could restore NIS functional expression. Based on the present study we can only conclude that the percentage of NIS expressing or PD-L1 expressing tumor cells does not correlate in the primary tumor of lymph node metastatic PTC.

Publisher

Research Square Platform LLC

Reference13 articles.

1. Biologic and Clinical Perspectives on Thyroid Cancer;Fagin JA;N Engl J Med,2016

2. Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer;Weitzman SP;Endocrinol Metab Clin North Am,2019

3. The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance;Dohán O;Endocr Rev,2003

4. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases;Dohán O;J Clin Endocrinol Metab,2001

5. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer;Yu Q;Asia Pac J Clin Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3